Dificid (fidaxomicin) prior authorization
Prior authorization criteria for coverage of fidaxomicin (Dificid) for treatment of C. difficile-associated diarrhea, intended for providers submitting requests to the payer's pharmacy benefit manager.
No material clinical or coverage changes in this revision.
Coverage Criteria for Dificid (fidaxomicin)
Initial Coverage Criteria
Covered when ALL of the following are met
Requested drug will be covered with prior authorization when criteria are met.
Use of Dificid should be limited to infections that are proven or strongly suspected to be caused by C. difficile. It is not indicated for treatment of other infections; culture/susceptibility data and local epidemiology should be considered when selecting or modifying antibacterial therapy.
Provider Actions, Documentation, and Authorization
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.